Metropolitan Life Insurance Company (MetLife)’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,697	Closed	-$108K	–	2620
2020 Q4	$108K	Buy	+4,697	New	+$59.5K	﹤0.01%	2321
2020 Q3	–	Sell	-5,055	Closed	-$75.3K	–	2607
2020 Q2	$75.3K	Hold	5,055	–	–	﹤0.01%	2409
2020 Q1	$61.6K	Buy	+5,055	New	+$80.4K	﹤0.01%	2315

Metropolitan Life Insurance Company (MetLife)'s PRVL Position: Q1 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 4,697 shares — an estimated $108K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PRVL in Q1 2020 and held it in 3 quarters. The position peaked at $108K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Metropolitan Life Insurance Company (MetLife) reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 4,697 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $108K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Prevail Therapeutics Inc. Common Stock in Q1 2020 and held it in 3 quarters.
Metropolitan Life Insurance Company (MetLife)'s Prevail Therapeutics Inc. Common Stock position peaked at $108K in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2021, filed 14 May 2021.